These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 15486408)
21. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma. Kabunga P; Coghlan G Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488 [TBL] [Abstract][Full Text] [Related]
22. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Benza RL; Barst RJ; Galie N; Frost A; Girgis RE; Highland KB; Strange C; Black CM; Badesch DB; Rubin L; Fleming TR; Naeije R Chest; 2008 Oct; 134(4):775-782. PubMed ID: 18625676 [TBL] [Abstract][Full Text] [Related]
23. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension. Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360 [TBL] [Abstract][Full Text] [Related]
24. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. Safdar Z Vasc Health Risk Manag; 2011; 7():119-24. PubMed ID: 21468170 [TBL] [Abstract][Full Text] [Related]
25. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Frost AE; Langleben D; Oudiz R; Hill N; Horn E; McLaughlin V; Robbins IM; Shapiro S; Tapson VF; Zwicke D; DeMarco T; Schilz R; Rubenfire M; Barst RJ Vascul Pharmacol; 2005 Jun; 43(1):36-9. PubMed ID: 15890561 [TBL] [Abstract][Full Text] [Related]
26. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension. Rondelet B; Dewachter L; Kerbaul F; Dewachter C; Hubloue I; Fesler P; Franck S; Remmelink M; Brimioulle S; Naeije R Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1118-23. PubMed ID: 20693396 [TBL] [Abstract][Full Text] [Related]
29. Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension. Souza R; Martins BC; Jardim C; Cortopassi F; Fernandes CJ; Pulido T; Sandoval J Int J Clin Pract; 2007 Jan; 61(1):153-6. PubMed ID: 17229188 [TBL] [Abstract][Full Text] [Related]
30. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. Beghetti M; Galiè N J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962 [TBL] [Abstract][Full Text] [Related]
31. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Sitbon O; Badesch DB; Channick RN; Frost A; Robbins IM; Simonneau G; Tapson VF; Rubin LJ Chest; 2003 Jul; 124(1):247-54. PubMed ID: 12853530 [TBL] [Abstract][Full Text] [Related]